iCAD is a global medical technology company headquartered in Nashua, New Hampshire. Founded in 1984, the firm develops artificial intelligence tools aimed at improving cancer detection, with a particular focus on breast health. Its technology is used across more than 50 countries, and its AI has been applied to over 40 million mammograms worldwide.
The company's principal offering is the ProFound Breast Health Suite, a portfolio of AI-driven technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation. iCAD's tools are integrated into nearly 30% of digital breast tomosynthesis exams globally, positioning the company as a significant player in AI-assisted radiology.
iCAD's work sits at the intersection of artificial intelligence, computer vision, and medical imaging. The company operates as part of DeepHealth and states a mission to broaden access to AI-powered mammography. Its technologies serve the medical technology, healthcare, radiology, and oncology sectors.
